Redirecting to https://myfox8.com/business/press-releases/cision/20250707NY24932/lutris-pharma-presents-additional-positive-data-from-its-phase-2-trial-of-lut014-gel-demonstrating-significant-efficacy-in-treating-acneiform-rash-associated-with-use-of-anti-egfr-cancer-therapies-at